SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-21-026012
Filing Date
2021-11-10
Accepted
2021-11-10 08:01:08
Documents
15
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20211109_8k.htm   iXBRL 8-K 28829
2 EXHIBIT 99.1 ex_305306.htm EX-99.1 105757
7 logo.jpg GRAPHIC 5918
  Complete submission text file 0001437749-21-026012.txt   288109

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dffn-20211110.xsd EX-101.SCH 3594
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20211110_def.xml EX-101.DEF 11425
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20211110_lab.xml EX-101.LAB 15311
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20211110_pre.xml EX-101.PRE 11585
8 EXTRACTED XBRL INSTANCE DOCUMENT dffn20211109_8k_htm.xml XML 2576
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 211394484
SIC: 2834 Pharmaceutical Preparations